A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Summary

This is a prospective, single arm, phase II study to evaluate the efficacy and safety of Envafolimab in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

Timeline

Start

2022-06

Primary completion

2024-06

Completion

2025-06

Drugs

Indications